A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: The RELEVANT Role of long dEtection window programming in patients with LEft VentriculAr dysfunction

European Heart Journal

Volumn 30, Issue 22, 2009, Pages 2758-2767

  Gasparini, Maurizio ^a   Menozzi, Carlo ^b   Proclemer, Alessandro ^c   Landolina, Maurizio ^d   Iacopino, Severio ^e   Carboni, Angelo ^f   Lombardo, Ernesto ^g   Regoli, Franois ^a   Biffi, Mauro ^h   Burrone, Valeria ⁱ   Denaro, Alessandra ⁱ   Boriani, Giuseppe ^h  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e Villa S Anna SpA   (Italy)

^f Azienda Ospedaliera   (Italy)

^g Reparto di Cardiochirurgia   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ NONE

Author keywords

Cardiac resynchronization therapy; Defibrillators; Implantable; Non ischaemic; Tachyarrhythmias

Indexed keywords

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DEFIBRILLATOR; EVENT FREE SURVIVAL; FEMALE; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE;

AGED; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHIES; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 72949114097     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp247     Document Type: Article

References (27)

1. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, Gasparini M, Linde C, Morgado FB, Oto A, Sutton R, Trusz-Gluza M, European Society of Cardiology. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association. Eur Heart J 2007;28:2256-2295.
2. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/ HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008;117:e350-e408.
3. Wathen MS, Sweeney MO, DeGroot PJ, Stark AJ, Koehler JL, Chisner MB, Machado C, Adkisson WO. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001;104:796-801.
4. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ, for the Pain Free Rx II Investigators. Prospective randomized multicenter trial of empirical antita-chycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) Trial Results. Circulation 2004;110:2591-2596.
5. Boriani G, Gasparini M, Lunati M, Santini M, Landolina M, Vincenti A, Curnis A, Bocchiardo M, Padeletti L, Biffi M, Allaria L, Denaro A. Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death. Am Heart J 2006;152:527.e521-527.e511.
6. Epstein AE, Carlson MD, Fogoros RN, Higgins SL, Venditti FJ. Classification of death in antiarrhythmia trials. J Am Coll Cardiol 1996;27:433-442.
7. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the Prospective Randomized Multicenter EMPIRIC Trial. J Am Coll Cardiol 2006;48:330-339.
8. Wilkoff B, Stern R, Williamson B, Wathen M, Holloman K, Fieberg A, Brown M. Strategic programming of detection and therapy parameters in implantable cardioverter defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008;52:541-550.
9. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K, Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003;289:2685-2694.
10. Maloney J, Masterson M, Khoury D, Trohman R, Wilkoff B, Simmons T, Morant V, Castle L. Clinical performance of the implantable cardioverter defibrillator: elec-trocardiographic documentation of 101 spontaneous discharges. Pacing Clin Elec-trophysiol 1991;14:280-285.
11. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, Schuger C, Steinberg JS, Higgins SL, Wilber DJ, Klein H, Andrews ML, Hall WJ, Moss AJ. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51: 1357-1365.
12. Klein RC, Raitt MH, Wilkoff BL, Beckman KJ, Coromilas J, Wyse DG, Friedman PL, Martins JB, Epstein AE, Hallstrom AP, Ledingham RB, Belco KM, Greene HL, AVIS Investigators. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmic versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electro-physiol 2003;14:940-948.
13. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 2004;15:1002-1009.
14. Avid Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. 1997;337:1576-1583.
15. Veltmann C, Borggrefe M, Schimpf R, Wolpert C. Fatal inappropriate ICD shock. J Cardiovasc Electrophysiol 2007;18:326-328.
16. Vollman D, Lüthje L, Vonhof S, Unterberg C. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm 2005; 307-309.
17. Tokano T, Bach D, Chang J, Davis J, Souza JJ, Zivin A, Knight BP, Goyal R, Man KC, Morady F, Strickberger SA. Effect of ventricular shock strength on cardiac hemo-dynamics. J Cardiovasc Electrophysiol 1998;9:791-797.
18. Steinbeck G, Dorwarth U, Mattke S, Hoffmann E, Markewitz A, Kaulbach H, Tassani P. Hemodynamic deterioration during ICD implant: Predictors of high-risk patients. Am Heart J 1994;127:1064-1067.
19. Benedini G, Marchini A, Curnis A, Bianchetti F, Gardini A, Pinetti P, Zanelli E. Implantable defibrillation and thromboembolic events. Pacing Clin Electrophysiol 1995;18:199-202.
20. Birk AV, Leno E, Robertson HD, Bolotina VM, Szeto HH. Interaction between ATP and catecholamines in stimulation of platelet aggregation. Am J Physiol Heart Circ Physiol 2003;284:H619-H625.
21. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-1017.
22. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940.
23. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-1480.
24. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA. Cost-effectiveness of implantable cardioverter defib-rillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997;126:1-12.
25. Boriani G, Biffi M, Martignani C, Valzania C, Diemberger I, Bertini M, Domenichini G, Branzi A. Is cardiac resynchronization therapy cost-effective? Europace 2009 (in press).
26. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circulation: Heart Failure 2008;1:98-106.
27. Piccini JP, Hernandez AF, Dai D, Thomas KL, Lewis WR, Yancy CW, Peterson ED, Fonarow GC, Get With the Guidelines Steering Committee, Hospitals. Use of cardiac resynchronization therapy in patients hospitalized with heart failure. Circulation 2008;118:926-933.